In summary, the down-regulation of DYRK2 remarkably reduced PCa tumor burden in vitro and in vivo, suggesting that DYRK2 played a critical function in regulating PCa and is a potential therapeutic target for the treatment of PCa. Here, DYRK2 is linked to posterior cortical atrophy.